

## ORIGINAL ARTICLE

# Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

A.H. Wei, H. Döhner, C. Pocock, P. Montesinos, B. Afanasyev,\* H. Dombret, F. Ravandi, H. Sayar, J.-H. Jang, K. Porkka, D. Selleslag, I. Sandhu, M. Turgut, V. Giai, Y. Ofran, M. Kizil Çakar, A. Botelho de Sousa, J. Rybka, C. Frairia, L. Borin, G. Beltrami, J. Čermák, G.J. Ossenkoppele, I. La Torre, B. Skikne, K. Kumar, Q. Dong, C.L. Beach, and G.J. Roboz, for the QUAZAR AML-001 Trial Investigators†

## ABSTRACT

**BACKGROUND**

Although induction chemotherapy results in remission in many older patients with acute myeloid leukemia (AML), relapse is common and overall survival is poor.

**METHODS**

We conducted a phase 3, randomized, double-blind, placebo-controlled trial of the oral formulation of azacitidine (CC-486, a hypomethylating agent that is not bioequivalent to injectable azacitidine), as maintenance therapy in patients with AML who were in first remission after intensive chemotherapy. Patients who were 55 years of age or older, were in complete remission with or without complete blood count recovery, and were not candidates for hematopoietic stem-cell transplantation were randomly assigned to receive CC-486 (300 mg) or placebo once daily for 14 days per 28-day cycle. The primary end point was overall survival. Secondary end points included relapse-free survival and health-related quality of life.

**RESULTS**

A total of 472 patients underwent randomization; 238 were assigned to the CC-486 group and 234 were assigned to the placebo group. The median age was 68 years (range, 55 to 86). Median overall survival from the time of randomization was significantly longer with CC-486 than with placebo (24.7 months and 14.8 months, respectively;  $P < 0.001$ ). Median relapse-free survival was also significantly longer with CC-486 than with placebo (10.2 months and 4.8 months, respectively;  $P < 0.001$ ). Benefits of CC-486 with respect to overall and relapse-free survival were shown in most subgroups defined according to baseline characteristics. The most common adverse events in both groups were grade 1 or 2 gastrointestinal events. Common grade 3 or 4 adverse events were neutropenia (in 41% of patients in the CC-486 group and 24% of patients in the placebo group) and thrombocytopenia (in 22% and 21%, respectively). Overall health-related quality of life was preserved during CC-486 treatment.

**CONCLUSIONS**

CC-486 maintenance therapy was associated with significantly longer overall and relapse-free survival than placebo among older patients with AML who were in remission after chemotherapy. Side effects were mainly gastrointestinal symptoms and neutropenia. Quality-of-life measures were maintained throughout treatment. (Supported by Celgene; QUAZAR AML-001 ClinicalTrials.gov number, NCT01757535.)

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Wei at Alfred Hospital, Commercial Rd., Melbourne, VIC 3004, Australia, or at [andrew.wei@monash.edu](mailto:andrew.wei@monash.edu).

\*Deceased.

†A list of the principal investigators in the QUAZAR AML-001 trial is provided in the Supplementary Appendix, available at [NEJM.org](http://NEJM.org).

N Engl J Med 2020;383:2526-37.

DOI: 10.1056/NEJMoa2004444

Copyright © 2020 Massachusetts Medical Society.

**A**CUTE MYELOID LEUKEMIA (AML) IS AN aggressive disease that predominantly affects older people.<sup>1</sup> Although complete remission is achieved with standard induction chemotherapy in 40 to 60% of patients older than 60 years of age who have AML, most patients (80 to 90%) eventually have a relapse.<sup>2-4</sup> Clonal evolution, epigenetic reprogramming leading to aberrant DNA methylation, and persistence of leukemia-initiating cells despite chemotherapy are thought to contribute to disease recurrence.<sup>5-8</sup>

Longer durations of first remission are associated with better survival outcomes.<sup>9</sup> Therefore, preventing early AML relapse with postremission therapy is an important goal. Although hematopoietic stem-cell transplantation (HSCT) after induction chemotherapy is potentially curative, this option is not feasible for many older patients.<sup>10</sup>

For patients who are not candidates for HSCT, effective AML maintenance therapies are needed that can reduce the risk of relapse and prolong overall survival without causing undue adverse effects or compromising health-related quality of life.<sup>4</sup> Although some studies have shown improvements in disease-free survival, no maintenance therapy has so far been shown to significantly prolong overall survival among patients with AML after standard intensive chemotherapy.<sup>11-18</sup> Consequently, maintenance therapy is not a widely established practice in the treatment of AML.

Until recently, no therapy was approved in the United States for use in patients with AML in remission after chemotherapy. Histamine dihydrochloride–interleukin-2 combination therapy is approved for use as maintenance therapy in the European Union on the basis of studies showing improvements in disease-free survival.<sup>19</sup> Although midostaurin is approved for use as maintenance therapy in the European Union for patients with *FLT3*-mutant AML,<sup>20</sup> the specific contribution of maintenance therapy is confounded by the use of midostaurin during induction and consolidation.<sup>21</sup> Hypomethylating agents are recommended by the National Comprehensive Cancer Network (NCCN) as maintenance therapy for older patients with AML on the basis of studies showing benefits with respect to disease-free survival but not overall survival.<sup>22</sup> Similarly, maintenance

approaches that involve cytotoxic chemotherapy have been found to improve disease-free survival.<sup>23</sup>

Oral azacitidine, known as CC-486, is a hypomethylating agent that can be administered in extended dosing schedules (for 14 or 21 days per 28-day treatment cycle) to sustain therapeutic activity.<sup>24</sup> The pharmacokinetic and pharmacodynamic profiles of CC-486 are distinct from those of injectable azacitidine,<sup>24,25</sup> and early studies showed that a response to CC-486 was achieved in some patients who had clinical resistance to injectable hypomethylating agents.<sup>26</sup> Here, we report results from the international, phase 3, double-blind, placebo-controlled QUAZAR AML-001 trial, in which CC-486 was evaluated as maintenance therapy in patients 55 years of age or older with AML in first remission after induction chemotherapy, with or without consolidation chemotherapy, who were not candidates for HSCT at trial entry.

## METHODS

### TRIAL DESIGN

We conducted this trial at 148 sites in 23 countries. The sponsor provided the drug and placebo and designed the trial in collaboration with the authors and an independent steering committee and with advice from regulatory agencies, in accordance with principles of the Declaration of Helsinki. The sponsor collected and analyzed the data and participated with the authors in its interpretation. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol, available with the full text of this article at NEJM.org. A professional writer paid by the sponsor assisted with preparation of the submitted manuscript. All the authors participated in revising the manuscript for submission and are fully responsible for its content. The protocol was approved by an institutional review board or ethics committee at each participating site. All the patients provided informed written consent. An independent data and safety monitoring committee assessed trial conduct and safety outcomes.

To be eligible for participation in the trial, patients had to be at least 55 years of age and to have newly diagnosed *de novo* AML (i.e., AML without an antecedent hematologic disorder) or secondary AML and intermediate- or poor-risk

cytogenetic characteristics at diagnosis (defined according to National Comprehensive Cancer Network 2011 guidelines<sup>27</sup>) (Fig. S1 in the Supplementary Appendix, available at NEJM.org). Patients were excluded if they were considered to be candidates for HSCT at the time of screening (there were no trial-specified criteria associated with transplantation eligibility). At screening, patients had to have an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 to 3 (scores range from 0 to 5, with higher scores indicating greater disability) and had to have recovered from induction chemotherapy with adequate marrow function (i.e., absolute neutrophil count  $\geq 0.5 \times 10^9$  per liter and platelet count  $\geq 20 \times 10^9$  per liter). The full list of inclusion and exclusion criteria is provided in the Supplementary Appendix. All patients had to have undergone induction chemotherapy, with or without consolidation therapy, before screening. Chemotherapy regimens were selected at the discretion of the treating physician.

Patients had to be in first complete remission or complete remission with incomplete blood count recovery within 4 months ( $\pm 7$  days) before randomization. Patients were randomly assigned in a 1:1 ratio to receive CC-486 (300 mg) or placebo, administered once daily on days 1 through 14 of repeated 28-day cycles. Assessment of remission status on the basis of bone marrow and peripheral blood examination was performed every 3 cycles during the first 24 cycles, at cycles 30 and 36, and as clinically indicated. Patients who were identified as having AML relapse with 5 to 15% blasts in blood or bone marrow during receipt of CC-486 or placebo could have their dosing regimen increased to 21 days per cycle at the discretion of the treating investigator. Administration of CC-486 or placebo continued until more than 15% blasts were present or unacceptable adverse effects occurred. All the patients could receive supportive care according to local practice.

#### END POINTS

The primary end point was overall survival, defined as the time from randomization to death from any cause. All patients were followed until death, withdrawal of consent, or loss to follow-up. The key secondary end point was relapse-free survival — the time from randomization to re-

lapse or death, whichever occurred first. Additional secondary end points included measures of safety and of the effect of CC-486 and placebo on health-related quality of life, assessed as changes from baseline in scores on the patient-reported Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale and three-level version of the European Quality of Life–5 Dimensions (EQ-5D-3L) questionnaires.

Central review of bone marrow and peripheral blood was conducted by a hematopathologist who was unaware of the treatment assignments. Complete remission with or without complete blood count recovery and AML relapse were defined according to International Working Group 2003 response criteria for AML.<sup>28</sup> The presence of measurable residual disease at trial entry was assessed centrally by means of flow cytometry, with the use of a leukemia-associated immunophenotype (LAIP)-based “different-from-normal” method with a 0.1% threshold for measurable residual disease positivity.

Safety was assessed among patients who received at least one dose of CC-486 or placebo. Adverse events were monitored through 28 days after the last dose. Prophylactic therapy for gastrointestinal or hematologic adverse events was permitted at the discretion of the treating investigator. AML relapse was not considered an adverse event for the purposes of the safety analysis.

#### STATISTICAL ANALYSIS

Detailed statistical methods are described in the Supplementary Appendix. Under the assumption of a median overall survival of 16.0 months in the placebo group<sup>29,30</sup> and 22.9 months in the CC-486 group, a trial duration of 60 months, a 5% dropout rate, and 330 deaths, enrollment of approximately 460 patients (230 per group) would provide 90% power to detect a hazard ratio of 0.70 and to show a significant difference in overall survival between the treatment groups. Sample-size calculations were based on a one-sided alpha of 0.025.

Overall and relapse-free survival were estimated with the use of the Kaplan–Meier method, and survival distributions were compared with a stratified log-rank test. Overall survival and then relapse-free survival were tested with the use of a sequential gate-keeping approach. The assumption of proportional hazards was tested with a

time-dependent Cox model with interaction terms of treatment and time and with a P value of 0.006. The proportional hazards assumption appeared to be violated, as indicated by the significant treatment-by-time interaction; thus, hazard ratios are not provided. Confidence intervals for survival estimates at 6 months, 1 year, and 2 years were calculated with Greenwood's variance formula.<sup>31</sup> No adjustments for multiplicity were made for other end points, and the resulting point estimates and 95% confidence intervals should not be used to infer treatment effects. We performed univariate analyses of overall and relapse-free survival in subgroups defined on the basis of clinically relevant baseline characteristics. Statistical methods relating to assessments of health-related quality of life are described in the Supplementary Appendix.

RESULTS

PATIENTS

From May 2013 through October 2017, a total of 472 patients were randomly assigned to receive either CC-486 (238 patients) or placebo (234 patients) (Fig. 1). Most patients (47 of 83) who were ineligible after screening had exceeded the acceptable 4-month period from attainment of remission to randomization. Three patients (2 in the CC-486 group and 1 in the placebo group) did not receive CC-486 or placebo and were excluded from safety analyses.

At data cutoff (July 15, 2019), 193 patients (81%) had discontinued CC-486 and 208 patients (89%) had discontinued placebo. The median time to discontinuation was 11.4 months (95% confidence interval [CI], 9.8 to 13.6) in the CC-486 group and 6.1 months (95% CI, 5.1 to 7.4) in the placebo group. AML relapse led to discontinuation of the trial regimen in 143 patients (60%) in the CC-486 group and 180 patients (77%) in the placebo group.

Baseline characteristics were generally balanced between the groups (Table 1, and Table S1). The median age in the overall trial population was 68 years (range, 55 to 86), and most patients had de novo AML (91%) and intermediate-risk cytogenetic characteristics (86%). All patients received induction with cytarabine-based regimens, in combination with an anthracycline or similar agent, before enrollment. In all, 80% of the pa-




Figure 1. Screening, Randomization, and Follow-up.

AML denotes acute myeloid leukemia, and HSCT hematopoietic stem-cell transplantation.

tients (186 [78%] in the CC-486 group and 192 [82%] in the placebo group) received at least one course of consolidation chemotherapy before trial entry, with 45% of all patients receiving one consolidation cycle and 31% receiving two consolidation cycles. The most common agents used for consolidation were cytarabine (in 377 of 378 patients), idarubicin (in 95 of 378), and daunorubicin (in 37 of 378). Among the patients who did not receive consolidation therapy, 25% initially received two cycles of induction chemotherapy. Thus, approximately 85% of patients had received

Characteristic	CC-486 (N=238)	Placebo (N=234)	Total (N=472)
Median age (range) — yr	68 (55–86)	68 (55–82)	68 (55–86)
Sex — no. (%)			
Male	118 (50)	127 (54)	245 (52)
Female	120 (50)	107 (46)	227 (48)
Type of AML — no. (%)			
De novo	213 (89)	216 (92)	429 (91)
Secondary	25 (11)	18 (8)	43 (9)
ECOG performance status score at screening — no. (%)†			
0	116 (49)	111 (47)	227 (48)
1	101 (42)	106 (45)	207 (44)
2 or 3	21 (9)	17 (7)	38 (8)
Cytogenetic risk at diagnosis — no. (%)			
Intermediate	203 (85)	203 (87)	406 (86)
Poor	35 (15)	31 (13)	66 (14)
Receipt of two or more courses of induction chemotherapy — no. (%)	49 (21)	41 (18)	90 (19)
Response after induction therapy — no. (%)			
Complete remission	187 (79)	197 (84)	384 (81)
Complete remission with incomplete blood count recovery	51 (21)	37 (16)	88 (19)
Receipt of consolidation therapy — no. (%)			
Yes	186 (78)	192 (82)	378 (80)
No	52 (22)	42 (18)	94 (20)
Median time from induction therapy to randomization (range) — mo	4.0 (1.4–8.8)	4.0 (1.3–15.1)	4.0 (1.3–15.1)
Median time from complete remission to randomization (range) — days‡	84.5 (7–154)	86.0 (7–263)	85.0 (7–263)
Median bone marrow blasts (range) — %§	2.0 (0.0–5.0)	2.0 (0.0–6.5)	2.0 (0.0–6.5)
Positive for measurable residual disease — no. (%)¶	103 (43)	116 (50)	219 (46)
Median platelet count (range) — $\times 10^9$ /liter§	154 (22–801)	179 (16–636)	165 (16–801)
Median absolute neutrophil count (range) — $\times 10^9$ /liter§	3.0 (0.3–15.9)	2.8 (0.5–9.6)	2.9 (0.3–15.9)

\* Percentages may not total 100 because of rounding. AML denotes acute myeloid leukemia.

† Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores indicating greater disability.

‡ Two patients in each group were enrolled after the inclusion window of 4 months ( $\pm 7$  days), which was a protocol violation.

§ Patients may have had multiple visits between screening and randomization. Although some of the values shown exceeded the eligibility criteria, all patients met relevant eligibility criteria at their screening visit.


¶ Measurable residual disease was determined by central assessment with flow cytometry, with the use of a leukemia-associated immunophenotype (LAIP)-based “different-from-normal” method with a 0.1% threshold for positivity.

two or more cycles of chemotherapy before enrollment.

The median time from complete remission to randomization was 85.0 days. At randomization, 5 patients (2%) in the CC-486 group and 11 (5%) in the placebo group were no longer in remission.

#### OVERALL SURVIVAL

At a median follow-up of 41.2 months, the median overall survival from the time of randomization was significantly longer in the CC-486 group than in the placebo group (24.7 months vs. 14.8 months;  $P < 0.001$ ) (Fig. 2A). The esti-




mated percentages of patients surviving at 1 year were 72.8% in the CC-486 group and 55.8% in the placebo group (difference, 17.0 percentage points; 95% CI, 8.4 to 25.6), and the corresponding percentages at 2 years were 50.6% and 37.1% (difference, 13.5 percentage points; 95% CI, 4.5 to 22.5).

The results for overall survival at 2 years from the time of randomization favored CC-486 in most subgroups based on disease characteristics at baseline (Fig. 3). An overall survival benefit was observed with CC-486 regardless of whether patients had received any consolidation therapy, had been in complete remission after induction

chemotherapy, or had had persistent measurable residual disease at randomization.

**RELAPSE-FREE SURVIVAL**

Relapse-free survival was significantly longer with CC-486 than with placebo (P<0.001). Median relapse-free survival from the time of randomization was 10.2 months with CC-486, as compared with 4.8 months with placebo (Fig. 2B). The estimated percentages of patients with relapse-free survival at 6 months were 67.4% in the CC-486 group and 45.2% in the placebo group (difference, 22.2 percentage points; 95% CI, 13.2 to 31.2), and the corresponding estimates at 1 year



**Figure 3. Univariate Analyses of Overall Survival at 2 Years in Patient Subgroups Defined on the Basis of Clinically Relevant Baseline Characteristics.** Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores indicating greater disability. CMML denotes chronic myelomonocytic leukemia, MDS myelodysplastic syndrome, MRD measurable residual disease, and WHO World Health Organization.

were 44.9% and 27.4% (difference, 17.5 percentage points; 95% CI, 8.5 to 26.4). The estimated time to onset of AML relapse is summarized in Table S2. Relapse-free survival at 1 year was generally higher with CC-486 than with placebo in patient subgroups defined on the basis of clinically relevant baseline characteristics (Fig. S2).

#### HEALTH-RELATED QUALITY OF LIFE

At baseline, patients reported relatively low levels of fatigue and physical impairment, and the FACIT Fatigue Scale and EQ-5D-3L scores were similar in the two treatment groups. No meaningful differences in FACIT Fatigue scores were noted between the groups across postbaseline visits (Fig. S3A). Similarly, EQ-5D-3L health utility index scores were similar in the two treatment groups at all visits except at cycles 22 and 23, when scores were numerically higher in the placebo group than in the CC-486 group (Fig. S3B). Mixed-effects models with repeated measures, which controlled for baseline health-related quality-of-life scores and other preselected covariates, showed no clinically meaningful differences in least-squares mean changes from baseline between the treatment groups at any visit, a finding that supported the noninferiority of CC-486 relative to placebo for health-related quality of life.

#### SAFETY

The median duration of receipt of CC-486 was 12 cycles (range, 1 to 80), and the median duration of receipt of placebo was 6 cycles (range, 1 to 73). In both groups, the most common adverse events that occurred during the period between the first dose and 28 days after the last dose of CC-486 or placebo were gastrointestinal events, including nausea, vomiting, and diarrhea (Table 2), which occurred more frequently with CC-486. CC-486–induced nausea and vomiting occurred mainly during cycles 1 and 2 (Table S3) and were less common during subsequent cycles after incorporation of antiemetic agents. The most common hematologic adverse events were neutropenia (in 44% of the patients in the CC-486 group and 26% of the patients in the placebo group), thrombocytopenia (in 33% and 27%), and anemia (in 20% and 18%) (Table 2). The percentages of patients with hematologic adverse events within each treatment group were generally consistent over time up to cycle 12 (Table S4). The

most common serious adverse events were infections, which were reported in 17% of patients in the CC-486 group and 8% of patients in the placebo group (Table S5).

Adverse events led to dosing interruptions for 43% of the patients in the CC-486 group and 17% of the patients in the placebo group (Table S6) and led to dose reductions in 16% and 3% of the patients, respectively (Table S7). Neutropenia was the most common adverse event leading to dose modifications in both groups. Adverse events led to discontinuation of the trial regimen in 13% of the patients in the CC-486 group and 4% of the patients in the placebo group (Table S8). The most common adverse events leading to discontinuation of CC-486 were gastrointestinal events, which were infrequent (5% of the patients in the CC-486 group and <1% of the patients in the placebo group). Three patients (1%) in each group discontinued the trial regimen because of a hematologic adverse event.

Adverse events led to death in nine patients (4%) in the CC-486 group: two died from sepsis, two from cerebral hemorrhage, one from both sepsis and multiorgan failure, and one each from intracranial hemorrhage, cardiogenic shock, aspiration pneumonia, and suicide. In the placebo group, adverse events led to death in four patients (2%): two died from multiorgan failure, one from cerebral hemorrhage, and one from general health deterioration.

#### ESCALATED DOSING

On identification of AML relapse with 5 to 15% blasts, 91 patients (51 [21%] in the CC-486 group and 40 [17%] in the placebo group) were assigned by their treating investigator to receive an escalated 21-day dosing schedule. The median time to escalated dosing was 9.2 months (range, 1.0 to 52.7) in the CC-486 group and 6.0 months (range, 0.5 to 19.3) in the placebo group. Patients received a median of two escalated dosing cycles in both the CC-486 group (range, 1 to 45) and the placebo group (range, 1 to 16); 43% of the patients in the CC-486 group received more than three escalated dosing cycles, as compared with 18% of the patients in the placebo group. Median overall survival from the time of randomization among these 91 patients was 22.8 months in the CC-486 group and 14.6 months in the placebo group. Among the 78 patients who had central confirmation of at least 5% blasts in



**Table 2. Adverse Events That Occurred in at Least 10% of Patients in Either Group.\***

Event	CC-486 (N=236)		Placebo (N=233)	
	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4
	<i>number of patients (percent)</i>			
Any adverse event	231 (98)	169 (72)	225 (97)	147 (63)
Nausea	153 (65)	6 (3)	55 (24)	1 (<1)
Vomiting	141 (60)	7 (3)	23 (10)	0
Diarrhea	119 (50)	12 (5)	50 (21)	3 (1)
Neutropenia	105 (44)	97 (41)	61 (26)	55 (24)
Constipation	91 (39)	3 (1)	56 (24)	0
Thrombocytopenia	79 (33)	53 (22)	63 (27)	50 (21)
Fatigue	70 (30)	7 (3)	45 (19)	2 (1)
Anemia	48 (20)	33 (14)	42 (18)	30 (13)
Asthenia	44 (19)	2 (1)	13 (6)	1 (<1)
Pyrexia	36 (15)	4 (2)	44 (19)	1 (<1)
Arthralgia	32 (14)	2 (1)	24 (10)	1 (<1)
Abdominal pain	31 (13)	2 (1)	16 (7)	0
Upper respiratory tract infection	31 (13)	1 (<1)	32 (14)	0
Decreased appetite	30 (13)	2 (1)	15 (6)	2 (1)
Cough	29 (12)	0	39 (17)	0
Febrile neutropenia	28 (12)	27 (11)	18 (8)	18 (8)
Back pain	28 (12)	3 (1)	23 (10)	2 (1)
Leukopenia	25 (11)	18 (8)	19 (8)	14 (6)
Pain in extremity	25 (11)	1 (<1)	12 (5)	0
Dizziness	25 (11)	0	21 (9)	0
Headache	23 (10)	0	26 (11)	1 (<1)
Peripheral edema	21 (9)	0	24 (10)	1 (<1)

\* Adverse events were evaluated from the date of the first dose of CC-486 or placebo through 28 days after the last dose. Events were coded according to preferred terms from the *Medical Dictionary of Regulatory Activities*, version 22, and were graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Patients are counted only once for multiple events within each preferred term.

their bone marrow on or before the first day of 21-day dosing, 10 of 43 patients (23%) in the CC-486 group and 4 of 35 patients (11%) in the placebo group had restoration of complete remission status while receiving the escalated dosing regimen. Hematologic events were the most common adverse events first reported during escalated dosing (Table S9).

#### SUBSEQUENT THERAPY

Most patients (307 [65%]) received at least one course of subsequent treatment after discontinu-

ation of the trial regimen, including 137 patients (58%) in the CC-486 group and 170 patients (73%) in the placebo group. Among the patients who had AML relapse during the trial, 96% of those in the CC-486 group and 94% of those in the placebo group received subsequent therapy. One third of the patients (33%) received an intensive chemotherapy regimen as salvage therapy (Table S10). Fifteen patients (6%) in the CC-486 group proceeded to HSCT: 6 remained in first remission at the time of HSCT, and 9 had a relapse. In the placebo group, 32 patients

(14%) underwent HSCT, all of whom had had a relapse.

## DISCUSSION

CC-486 maintenance therapy provided a significant prolongation of both overall and relapse-free survival among older patients with AML who were in remission after intensive chemotherapy with or without consolidation therapy. The results for overall and relapse-free survival favored CC-486 in most subgroups based on age, sex, cytogenetic risk, initial response to induction chemotherapy, receipt of consolidation therapy, or measurable residual disease status at trial entry.

Median relapse-free survival in the CC-486 group was more than twice that in the placebo group, which probably explains the superior overall survival with CC-486. In this trial, the median time from complete remission to randomization was approximately 3 months, and both overall and relapse-free survival were measured from the time of randomization, whereas other studies have measured survival from the time of induction or soon after attainment of complete remission.<sup>14,21,32</sup> In addition, the frequency of bone marrow evaluation in this trial (required every 3 months) facilitated the recognition of early, subclinical relapse. Thus, cross-study comparisons of time-to-event estimates should be made with caution.

A formidable challenge to effective maintenance therapy in AML is the genomic and epigenomic complexity of the disease.<sup>33-35</sup> As compared with targeted therapies, epigenetic reprogramming with hypomethylating agents may offer broad antileukemic activity in a disease that has substantial biologic heterogeneity.<sup>33,34</sup> The antitumor activity of hypomethylating agents is thought to include reactivation of silenced tumor suppressor genes through DNA hypomethylation<sup>36,37</sup> and the induction of cytotoxicity-mediated DNA damage and apoptosis.<sup>36,38</sup> Although parenteral azacitidine and CC-486 have the same active ingredient, they are not bioequivalent<sup>25</sup> and cannot be used interchangeably. The significant clinical benefits of CC-486 in delaying relapse and prolonging survival may reflect the pharmacodynamic effect of extending drug exposure and sustaining epigenetic regula-

tion over the course of the treatment cycle.<sup>24</sup> Maintenance therapy with injectable azacitidine has been investigated in other trials, including the U.K. National Cancer Research Institute AML16 trial, involving patients with AML or high-risk myelodysplastic syndromes.<sup>39</sup> Although there are important differences between that trial and our trial, maintenance therapy with injectable azacitidine in that trial did not provide a survival benefit over no maintenance therapy among patients who had received one previous consolidation cycle or in those who had measurable residual disease after induction chemotherapy. In contrast, benefits with respect to both relapse-free survival and overall survival were shown with CC-486 in this trial, regardless of receipt of consolidation therapy or the presence of measurable residual disease at randomization. The convenience of oral CC-486 dosing may also improve adherence and promote longer-term treatment than is practical with injectable agents.

Treatment-related adverse effects have been a deterrent to the use of maintenance therapy in patients with AML.<sup>18</sup> In our trial, CC-486 was associated with an adverse-event profile similar to that of injectable azacitidine, and health-related quality of life was preserved.<sup>40,41</sup> Nausea, vomiting, and diarrhea were the most frequent adverse events with CC-486, but the frequency of these events decreased after the first two treatment cycles, perhaps aided by implementation of antiemetics, antidiarrheals, and dose modifications. Treatment discontinuation due to these events was infrequent. Neutropenia is a known side effect of hypomethylating therapy<sup>40,41</sup>; dosing modifications and the use of granulocyte colony-stimulating factor (G-CSF) may be useful to consider, as clinically indicated. Few patients (approximately 1%) discontinued CC-486 because of hematologic adverse events.

Determining which molecular characteristics may influence outcomes of maintenance therapy could be useful for identifying patients who are likely to derive the most benefit from this approach. Although assessment of molecular abnormalities was not required for this trial, correlative samples were obtained for potential future analysis.

Despite demonstrable survival advantages with CC-486 maintenance therapy, the risk of eventual relapse and death from AML remains prob-

lematic. Whether CC-486 may benefit patients with AML when it is used in other clinical contexts requires further investigation. Results from an open-label phase 2 study suggest that CC-486 may provide effective maintenance therapy after HSCT,<sup>42</sup> but larger, controlled trials are needed.

In this trial, CC-486 maintenance therapy prolonged overall and relapse-free survival among patients with AML who were in remission after intensive chemotherapy. Side effects were mainly gastrointestinal adverse events, which were controllable with antiemetics and antidiarrheal agents, and neutropenia, which was managed

with hematopoietic growth factors and CC-486 dose modifications. Discontinuation of CC-486 therapy owing to adverse events was uncommon. Quality of life was maintained during treatment.

Supported by Celgene (a wholly owned subsidiary of Bristol Myers Squibb).

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

We thank the patients, families, coinvestigators, and all personnel who participated in this trial; and Sheila Truten, Brian Kaiser, and Kelly Dittmore (of Medical Communication Company) for editorial and writing assistance with an early draft of the manuscript, funded by the sponsor.

#### APPENDIX

The authors' full names and academic degrees are as follows: Andrew H. Wei, M.B., B.S., Ph.D., Hartmut Döhner, M.D., Christopher Pocock, M.B., B.S., Pau Montesinos, M.D., Ph.D., Boris Afanasyev, M.D., D.Sci., Hervé Dombret, M.D., Farhad Ravandi, M.D., Hamid Sayar, M.D., Jun-Ho Jang, M.D., Ph.D., Kimmo Porkka, M.D., Dominik Selleslag, M.D., Irwindeep Sandhu, M.D., Mehmet Turgut, M.D., Valentina Giai, M.D., Ph.D., Yishai Ofran, M.D., Merih Kizil Çakar, M.D., Aida Botelho de Sousa, M.D., Justyna Rybka, M.D., Ph.D., Chiara Frairia, M.D., Lorenza Borin, M.D., Germana Beltrami, M.D., Jaroslav Čermák, M.D., Ph.D., Gert J. Ossenkoppele, M.D., Ph.D., Ignazia La Torre, M.D., Barry Skikne, M.D., Keshava Kumar, Ph.D., Qian Dong, Dr.P.H., C.L. Beach, Pharm.D., and Gail J. Roboz, M.D.

The authors' affiliations are as follows: the Department of Clinical Haematology, Alfred Hospital, and the Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia (A.H.W.); the Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany (H. Döhner); Kent and Canterbury Hospital, Canterbury, United Kingdom (C.P.); Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, and Hospital Universitario i Politècnic La Fe, Valencia — both in Spain (P.M.); Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology, and Transplantation, Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia (B.A.); the Department of Hematology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, and Institut de Recherche Saint-Louis, Université de Paris, Paris (H. Dombret); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (F.R.); Indiana University Cancer Center, Indianapolis (H.S.); Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (J.H.J.); Hospital District of Helsinki and Uusimaa (HUS) Comprehensive Cancer Center, Hematology Research Unit Helsinki and iCAN Digital Precision Cancer Center Medicine Flagship, University of Helsinki, Helsinki (K.P.); AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium (D.S.); University of Alberta Hospital, Edmonton, Canada (L.S.); Ondokuz Mayıs University, Samsun (M.T.), and Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara (M.K.C.) — both in Turkey; Antonio e Biagio e Cesare Arrigo Hospital, Alessandria (V.G.), Città della Salute e della Scienza, Turin (C.F.), Ospedale San Gerardo Monza, Monza (L.B.), and Ospedale Policlinico San Martino, Genoa (G.B.) — all in Italy; Rambam Medical Center and Faculty of Medicine Technion, Haifa, Israel (Y.O.); Hospital dos Capuchos, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal (A.B.S.); Wrocław Medical University, Wrocław, Poland (J.R.); Ústav Hematologie a Krevní Transfúze, Prague, Czech Republic (J.C.); Amsterdam University Medical Center, Location VUMC (Vrije Universiteit Medical Center), Amsterdam (G.J.O.); Celgene (Bristol Myers Squibb), Boudry, Switzerland (I.L.T.); Bristol Myers Squibb, Princeton, NJ (B.S., K.K., Q.D., C.L.B.); University of Kansas Medical Center, Kansas City (B.S.); and Weill Cornell Medicine and New York Presbyterian Hospital, New York (G.J.R.).

#### REFERENCES

- National Cancer Institute. Cancer stat facts: leukemia — acute myeloid leukemia (AML) (<https://seer.cancer.gov/statfacts/html/amyl.html>).
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood* 2017; 129:424-47.
- Schlenk RF, Frech P, Weber D, et al. Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. *Leukemia* 2017;31:1217-20.
- Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. *Am J Hematol* 2019;94:803-11.
- Ravandi F, Walter RB, Freeman SD. Evaluating measurable residual disease in acute myeloid leukemia. *Blood Adv* 2018; 2:1356-66.
- Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. *Nat Rev Clin Oncol* 2013;10:460-71.
- Ossenkoppele G, Schuurhuis GJ. MRD in AML: time for redefinition of CR? *Blood* 2013;121:2166-8.
- Vosberg S, Greif PA. Clonal evolution of acute myeloid leukemia from diagnosis to relapse. *Genes Chromosomes Cancer* 2019;58:839-49.
- Breems DA, Van Putten WLJ, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. *J Clin Oncol* 2005;23:1969-78.
- Molica M, Breccia M, Foa R, Jabbour E, Kadia TM. Maintenance therapy in AML: the past, the present and the future. *Am J Hematol* 2019;94:1254-65.
- Palva IP, Almqvist A, Elonen E, et al. Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia. *Eur J Haematol* 1991;47:229-33.
- Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. *Blood* 2001;98:1302-11.
- Buyse M, Squifflet P, Lange BJ, et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance ther-

- apy in acute myeloid leukemia. *Blood* 2011;117:7007-13.
14. Huls G, Chitu DA, Havelange V, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. *Blood* 2019;133:1457-64.
  15. Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. *Blood* 2006;108:88-96.
  16. Blum W, Sanford BL, Klisovic R, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). *Leukemia* 2017;31:34-9.
  17. Löwenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy — the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. *J Clin Oncol* 1998;16:872-81.
  18. Löwenberg B, Beck J, Graux C, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. *Blood* 2010;115:2586-91.
  19. Ceplene (histamine dihydrochloride): summary of product characteristics. London: European Medicines Agency ([https://www.ema.europa.eu/en/documents/product-information/ceplene-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/ceplene-epar-product-information_en.pdf)).
  20. Rydapt (midostaurin): summary of product characteristics. London: European Medicines Agency ([https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf)).
  21. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a *FLT3* mutation. *N Engl J Med* 2017;377:454-64.
  22. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology for acute myeloid leukemia, version 3.2020. 2019.
  23. Büchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. *J Clin Oncol* 1985;3:1583-9.
  24. Laille E, Shi T, Garcia-Manero G, et al. Pharmacokinetics and pharmacodynamics with extended dosing of CC-486 in patients with hematologic malignancies. *PLoS One* 2015;10(8):e0135520.
  25. Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. *J Clin Oncol* 2011;29:2521-7.
  26. Garcia-Manero G, Savona MR, Gore SD, et al. CC-486 (oral azacitidine) in patients with hematological malignancies who had received prior treatment with injectable hypomethylating agents (HMAs): results from phase 1/2 CC-486 studies. *Blood* 2016;128:905. abstract.
  27. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology for acute myeloid leukemia. 2011.
  28. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *J Clin Oncol* 2003;21:4642-9.
  29. Baer MR, George SL, Sanford BL, et al. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. *Leukemia* 2011;25:800-7.
  30. Baer MR, George SL, Sanford BL, et al. Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: analysis of four CALGB studies. *J Clin Oncol* 2010;28(Suppl):6531 abstract.
  31. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons, 1980.
  32. Grövdal M, Karimi M, Khan R, et al. Maintenance treatment with azacitidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. *Br J Haematol* 2010;150:293-302.
  33. Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. *Blood* 2016;127:29-41.
  34. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med* 2013;368:2059-74.
  35. Li S, Garrett-Bakelman FE, Chung SS, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. *Nat Med* 2016;22:792-9.
  36. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacitidine and decitabine. *Int J Cancer* 2008;123:8-13.
  37. Stresemann C, Bokelmann I, Mählknecht U, Lyko F. Azacitidine causes complex DNA methylation responses in myeloid leukemia. *Mol Cancer Ther* 2008;7:2998-3005.
  38. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. *PLoS One* 2010;5(2):e9001.
  39. Burnett A, Russell N, Freeman S, et al. A comparison of limited consolidation chemotherapy therapy or not, and demethylation maintenance or not in older patients with AML and high risk MDS: long term results of the UK NCRI AML16 trial. *Haematologica* 2015;100:S513. abstract.
  40. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol* 2009;10:223-32.
  41. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. *Blood* 2015;126:291-9.
  42. de Lima M, Oran B, Champlin RE, et al. CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. *Biol Blood Marrow Transplant* 2018;24:2017-24.

Copyright © 2020 Massachusetts Medical Society.